论文部分内容阅读
目的:探讨华法林对高龄房颤并发栓塞患者的抗凝剂量、效果和不良反应。方法:对18例高龄房颤并发栓塞患者应用华法林(每片2.5 mg),每日1次早饭后口服,维持剂量为(2.26±0.30)mg,监测国际标准化比率(INR)。结果:本组患者华法林在(10.6±3.5)d内使INR达标(1.5～2.5),这一维持剂量的出血不良反应轻微。结论:高龄房颤患者并发脑栓塞和下肢动脉栓塞后,华法林的应用没有特殊要求,较普通人小的剂量可使INR达标。
Objective: To investigate the anticoagulant dosage, effect and adverse reaction of warfarin in elderly patients with atrial fibrillation complicated with embolism. Methods: 18 elderly patients with atrial fibrillation and embolism were treated with warfarin (2.5 mg per tablet). After breakfast once daily, the dosage was adjusted to (2.26 ± 0.30) mg. The international standardized ratio (INR) was monitored. RESULTS: Warfarin in this group achieved an INR (1.5-2.5) within 10.6 ± 3.5 days, with a slight bleeding-related adverse effect at this maintenance dose. CONCLUSIONS: There is no specific requirement for the use of warfarin in patients with advanced AF who have cerebral embolism and arterial embolism of the lower extremities. The smaller dose than warfarin can achieve INR compliance.